The exact origins of SARS-CoV-2 are still something of a mystery, but new research may bring scientists one step closer to an explanation for how the virus reached Wuhan. Also in the episode, we dive into GEN’s coverage of the annual AACR meeting including how the community is navigating massive research budget cuts. Then we discuss a potential colorectal cancer therapy using CRISPR-edited tumor infiltrating lymphocytes and a method for delivering protein therapies and gene editors using engineered vesicles. Lastly, in business news, Recursion rethinks its pipeline, the FDA gives Abeona’s gene therapy a chance, and Bristol Myers Squibb execs open up on artificial intelligence.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Julianna LeMieux, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

Listed below are links to the GEN stories referenced in this episode of Touching Base:

AACR 2025: A Video Update from Chicago

By Julianna LeMieux, PhD and Damian Doherty, GEN, April 29, 2025

Hope and Headwinds at AACR in Chicago

By Damian Doherty, GEN, April 29, 2025

Senator Tammy Baldwin Supports Science in AACR Speech

By Julianna LeMieux, PhD, GEN, April 29, 2025

CRISPR-Edited TILs Fight Advanced Colorectal Cancer in Patients

By GEN, May 4, 2025

Engineered Extracellular Vesicles Could Deliver Gene Editors, Therapeutic Proteins to Cells

By GEN, April 30, 2025

SARS-CoV-2 Likely Spread Through Wildlife Trade, Not Bat Migration

By GEN, May 7, 2025

Chatting with Author David Quammen about SARS-CoV-2 Will Leave You “Breathless”

Originally aired: November 16, 2022

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus

By Alex Philippidis, GEN Edge, May 5, 2025

StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy

By Alex Philippidis, GEN Edge, May 4, 2025

Predict First: BMS Executives Discuss Company’s AI Approach

By Alex Philippidis, GEN Edge, March 26, 2025

Hosted on Acast. See acast.com/privacy for more information.